Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

| * * * | * * | * * | * * | * Welcome to STN International * * * * * * * * * * |
|--------------|--------|-----|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NEWS NEWS | 1 2 | NOV | 21 | Web Page for STN Seminar Schedule - N. America CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, |
| | _ | | | and Japanese-language basic patents from 2004-present |
| NEWS | 3 | NOA | | MARPAT enhanced with FSORT command |
| NEWS | 4 | NOA | | CHEMSAFE now available on STN Easy |
| NEWS | 5 | NOV | 26 | Two new SET commands increase convenience of STN searching |
| NEWS | 6 | DEC | 01 | ChemPort single article sales feature unavailable |
| NEWS | 7 | DEC | 12 | GBFULL now offers single source for full-text coverage of complete UK patent families |
| NEWS | 8 | DEC | 17 | Fifty-one pharmaceutical ingredients added to PS |
| NEWS | 9 | JAN | | The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo |
| NEWS | 10 | JAN | 07 | WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data |
| NEWS | 11 | FEB | 02 | Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE |
| NEWS | 12 | FEB | Λ2 | GENBANK enhanced with SET PLURALS and SET SPELLING |
| NEWS | | FEB | | Patent sequence location (PSL) data added to USGENE |
| NEWS | | FEB | | COMPENDEX reloaded and enhanced |
| NEWS | | FEB | | WTEXTILES reloaded and enhanced |
| NEWS | | | | |
| NEWS | 10 | FEB | 19 | New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art |
| NEWS | 17 | FEB | 19 | Increase the precision of your patent queries use terms from the IPC Thesaurus, Version 2009.01 |
| NEWS | 18 | FEB | 23 | Several formats for image display and print options discontinued in USPATFULL and USPAT2 |
| NEWS | 19 | FEB | 23 | MEDLINE now offers more precise author group fields and 2009 MeSH terms |
| NEWS | 20 | FEB | 23 | TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms |
| NEWS | 21 | FEB | 23 | Three million new patent records blast AEROSPACE into STN patent clusters |
| NEWS | 22 | FEB | 25 | USGENE enhanced with patent family and legal status display data from INPADOCDB |
| NEWS | 23 | MAR | 06 | INPADOCDB and INPAFAMDB enhanced with new display formats |
| | | | | |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * STN Columbus

FILE 'HOME' ENTERED AT 12:57:19 ON 06 MAR 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

> 0.22 0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:57:27 ON 06 MAR 2009 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 MAR 2009 HIGHEST RN 1115640-24-8 DICTIONARY FILE UPDATES: 4 MAR 2009 HIGHEST RN 1115640-24-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\STNEXP\Queries\10599918 I to III.str

```
chain nodes :
10 11 12 19
                                                                  21 22
                                                                                                      23 33 34 35 42 44
                                                                                                                                                                                                            45
                                                                                                                                                                                                                               46
                                                                                                                                                                                                                                               47
                                                                                                                                                                                                                                                                   48
                                                                                                                                                                                                                                                                                    49
                                                                                                                                                                                                                                                                                                       50
                                                                                                                                                                                                                                                                                                                        51
                                                                                                                                                                                                                                                                                                                                         52 53
54 55 56 57 58 59
ring nodes :
                                                                                                                                                                                                                                                                             27
1 2 3 4
                                                5 6 7 8
                                                                                                        9 13 14 15 16 17 18 24 25 26
                                                                                                                                                                                                                                                                                                  28
                                                                                                                                                                                                                                                                                                                    29
                                                                                                                                                                                                                                                                                                                                    30
32 36 37
                                                  38 39 40
                                                                                                      41
chain bonds :
1-21 2-22 8-10 9-23 10-11 10-12 12-19 24-44 25-45
                                                                                                                                                                                                                                                             31-33 32-46 33-34
35
35-42 46-47 46-48 48-49 48-53 49-50 49-54 50-51 50-56 51-52 52-55 56-57
56-58 58-59
ring bonds :
1-2 \quad 1-6 \quad 1-7 \quad 2-3 \quad 2-9 \quad 3-4 \quad 4-5 \quad 5-6 \quad 7-8 \quad 8-9 \quad 13-14 \quad 13-18 \quad 14-15 \quad 15-16 \quad 16-17
17-18 24-25 24-29 24-30 25-26 25-32 26-27 27-28 28-29 30-31 31-32 36-37
36-41 37-38
38-39 39-40 40-41
exact/norm bonds :
2-9 \quad 8-9 \quad 10-11 \quad 10-12 \quad 25-32 \quad 31-32 \quad 32-46 \quad 33-34 \quad 33-35 \quad 46-47 \quad 48-49 \quad 49-50 \quad 56-47 \quad 48-49 \quad 49-50 \quad 
57
56-58
exact bonds :
1-2 \quad 1-6 \quad 1-7 \quad 1-21 \quad 2-3 \quad 2-22 \quad 3-4 \quad 4-5 \quad 5-6 \quad 7-8 \quad 8-10 \quad 9-23 \quad 12-19 \quad 24-25 \quad 24-29
24 - 30 \quad 24 - 44 \quad 25 - 26 \quad 25 - 45 \quad 26 - 27 \quad 27 - 28 \quad 28 - 29 \quad 30 - 31 \quad 31 - 33 \quad 35 - 42 \quad 46 - 48 \quad 48 - 53 \quad 27 - 28 \quad 28 - 29 \quad 30 - 31 \quad 31 - 33 \quad 35 - 42 \quad 46 - 48 \quad 48 - 53 \quad 48 -
                          50-51
49-54
50-56 51-52 52-55
                                                                                          58-59
normalized bonds :
13-14 \quad 13-18 \quad 14-15 \quad 15-16 \quad 16-17 \quad 17-18 \quad 36-37 \quad 36-41 \quad 37-38 \quad 38-39 \quad 39-40 \quad 40-41
isolated ring systems:
containing 1 : 24 :
Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom
                                                                                                                                                                                                                                                 17:Atom 18:Atom 19:CLASS
20:Atom 21:CLASS
22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
33:CLASS 34:CLASS 35:CLASS 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom
42:CLASS
43:Atom 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS
51:CLASS 52:CLASS
53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS
fragments assigned product role:
containing 24
fragments assigned reactant/reagent role:
containing 1
L1
```

STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS L1STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file casreact COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.48 0.70

FULL ESTIMATED COST

FILE 'CASREACT' ENTERED AT 12:57:54 ON 06 MAR 2009 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 2 Mar 2009 VOL 150 ISS 10

New CAS Information Use Policies, enter HELP USAGETERMS for details.

****************** CASREACT now has more than 16.5 million reactions

CASREACT contains reactions from CAS and from: ZIC/VINITI database (1974-1999) provided by InfoChem; INPI data prior to 1986; Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich; organic reactions, portions copyright 1996-2006 John Wiley & Sons, Ltd., John Wiley and Sons, Inc., Organic Reactions Inc., and Organic Syntheses Inc. Reproduced under license. All Rights Reserved.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11 SSS full

FULL SEARCH INITIATED 12:57:58 FILE 'CASREACT' SCREENING COMPLETE - 165 REACTIONS TO VERIFY FROM 26 DOCUMENTS

100.0% DONE 165 VERIFIED 39 HIT RXNS 15 DOCS

SEARCH TIME: 00.00.01

L215 SEA SSS FUL L1 (39 REACTIONS)

=> d ibib abs fhit 1-YOU HAVE REQUESTED DATA FROM 15 ANSWERS - CONTINUE? Y/(N):y

L2 ANSWER 1 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 149:386408 CASREACT Full-text

TITLE: Process for the preparation of perindopril erbumine

salt and novel polymorph (s) thereof

Desai, Parimal Hansmukh; Salvi, Narenda Jagannath; INVENTOR(S):

Patravale, Bharatkumar Surendra; Subramanian,

Seetharaman; Kajale, Nitin Baburao; Dabe, Avikumar

Digamber

PATENT ASSIGNEE(S): Aarti Healthcare Limited, India

SOURCE: PCT Int. Appl., 26pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PA' | rent | NO. | | KI | ND : | DATE | | | A. | PPLI | CATI | ON NO | Э. | DATE | | | |
|-----|------|------|-----|-----|------|------|------|-----|-----|----------|-------------------|-------|-----|-------|------|-----|-----|
| | | | | | : | | | | | | | | | | | | |
| WO | 2008 | 1142 | 70 | A | 1 : | 2008 | 0925 | | M | 20 | 07-II | N120 | | 20070 | 0322 | | |
| | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BH, | BR, | BW, | BY, | ΒZ, | CA, |
| | | CH, | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FΙ, | GB, |
| | | GD, | GE, | GH, | GM, | GT, | HN, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | ΚE, | KG, | ΚM, |
| | | KN, | KΡ, | KR, | KΖ, | LA, | LC, | LK, | LR, | LS, | LT, | LU, | LY, | MA, | MD, | ME, | MG, |
| | | MK, | MN, | MW, | MX, | MY, | MΖ, | NA, | NG, | NI, | NO, | NZ, | OM, | PG, | PH, | PL, | PT, |
| | | RO, | RS, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SM, | SV, | SY, | ТJ, | TM, | TN, | TR, |
| | | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | ZA, | ZM, | ZW | | | | | |
| | RW: | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | ΗU, | ΙE, |
| | | IS, | IT, | LT, | LU, | LV, | MC, | MT, | NL, | PL_{r} | PT, | RO, | SE, | SI, | SK, | TR, | BF, |
| | | ВJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML_{r} | MR, | NE, | SN, | TD, | ΤG, | BW, |
| | | GH, | GM, | ΚE, | LS, | MW, | MZ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, | ΑZ, |
| | | BY, | KG, | KΖ, | MD, | RU, | ΤJ, | TM | | | | | | | | | |

PRIORITY APPLN. INFO.: WO 2007-IN120 20070322

AB. This invention relates to single not process for the preparation

This invention relates to single pot process for the preparation of perindopril erbumine salt according to which condensation of (2S, 3aS, 7aS)-octahydroindole-2-carboxylic acid benzyl ester para toluene sulfonate with N-((S-)-ethoxy carbonyl -1-ethyl-(S)-alanine) catalytic hydrogenation of benzyl ester of (2S, 3aS, 7aS)-1-{2-[1-(ethoxycarbonyl)-(S)-butylamino]-(S)propionyl}- octahydro-indole-2-carboxylate and conversion of (2S,3aS, 7aS)-1-{2-[1-(ethoxycarbonyl)-(S)-butylamino]-(S)- propionyl}-octahydroindole-2-carboxylic acid to its perindopril erbumine salt are carried out in a single pot using a single solvent such as iso-Pr acetate to obtain perindopril erbumine salt of very high purity. Also a novel polymorph S of perindopril erbumine having X-ray diffraction peaks of 9.10, 14.64, 15.37, 16.58, 17.39, 19.99, 20.62, 21.50, 22.15, 22.60, 24.20, 27.55 ± 0.2 at 2Θ values. Also processes for preparing the novel polymorph S.

RX(1) OF 6 A + B ===> C...

$$HO_3S$$
A: CM 1

 HO_3S
 $A: CM 2$
 HO_3S
 HO_3S

С

RX(1) RCT A 94062-52-9, B 82834-12-6

PRO C 122454-52-8

SOL 108-21-4 Acetic acid, 1-methylethyl ester, 121-44-8 Et3N, 2592-95-2 1-Benzotriazolol, 25952-53-8 EDAP

CON SUBSTAGE(1) 25 - 30 deg C SUBSTAGE(2) 5 - 10 deg C

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 148:55381 CASREACT Full-text

TITLE: Process for the preparation of perindopril and

intermediates thereof

INVENTOR(S): Haider, Akhtar; Megevand, Sophie; Nicollier, Brigitte;

Pannatier, Yvan

PATENT ASSIGNEE(S): Sochinaz SA, Switz. SOURCE: Eur. Pat. Appl., 19pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,

BA, HR, MK, YU

PRIORITY APPLN. INFO.: EP 2006-11981 20060609

OTHER SOURCE(S): MARPAT 148:55381

GΙ

AB The invention provides a novel method for the synthesis of (2S,3αS,7αS) - octahydroindole-2-carboxylic acid (I) and its aryl esters II [wherein X, Y = H, halo, alkyl, alkoxyl or nitro group], and the conversion of the p-nitrobenzyl ester of the acid into perindopril or its salts. II were obtained via esterification of racemic octahydroindole-2-carboxylic acid hydrochloride with benzyl alcs. in the presence of aryl sulfonic acids such as p-TsOH, followed by resolution with such as dibenzoyl-(L)-tartaric acid. Alternatively, II could be synthesized directly by esterification of chiral I with benzyl alcs. For example, I was reacted with p-nitrobenzyl alc. in the presence of p-TsOH to afford p-tosylate salt of the corresponding ester in 79% yield, which underwent DCC/HOBt-mediated coupling reaction with N-[(S)-1-(ethoxycarbonyl)butyl]-(S)-alanine in dichloromethane (80% yield). Pd/C-catalyzed hydrogenolysis of the resultant p-nitrobenzyl ester led to perindopril.

$$RX(5)$$
 OF 21 ...R + Q ===> S...

$$\begin{array}{c} \text{Me} \\ \text{NH} \\ \text{n-Pr} \\ \end{array}$$
 OEt
$$\begin{array}{c} \text{Me} \\ \text{HO}_{3S} \\ \end{array}$$
 R Q: CM 1

Q: CM 2
$$(5)$$

S YIELD 80%

RX(5) RCT R 82834-12-6

STAGE (1)

SOL 75-09-2 CH2C12

CON 10 minutes, room temperature

STAGE (2)

RCT Q 959984-64-6

RGT T 121-44-8 Et3N, U 2592-95-2 1-Benzotriazolol

SOL 75-09-2 CH2C12

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) 15 minutes, room temperature

STAGE (3)

RGT V 538-75-0 DCC

CON SUBSTAGE(1) room temperature -> 5 deg C

SUBSTAGE(3) 5 hours, room temperature

SUBSTAGE(4) 1 hour, room temperature -> 5 deg C

PRO S 866430-96-8

NTE workup

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 15 CASREACT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 147:212285 CASREACT Full-text
TITLE: Process for the preparation of

N-[1-(S)-ethoxycarbonyl-1-butyl]-(s)-alanine-DMT

complex and its use in the preparation of perindopril

INVENTOR(S): Joshi, Narendra Shriram; Pradhan, Nitin Sharad Chandra

PATENT ASSIGNEE(S): Glenmark Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 16pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2007085933
                       A2
                            20070802
                                           WO 2007-IB150
                                                             20070123
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:
                                            IN 2006-MU125
                                                             20060125
                                            US 2006-792875P
                                                             20060418
OTHER SOURCE(S):
                         MARPAT 147:212285
GΙ
```

AB A process for the preparation of N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine-DMT complex (I) by reaction of N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride in a solvent and its use in the synthesis of perindopril, perindopril erbumine or pharmaceutically acceptable salts by reaction of I with compound (II) (R1 = aryl, alkyl, or silyl protective group) in a solvent, following by deprotection of compound (III) using suitable deprotecting agent, is described. Thus, N-[1-(S)-ethoxycarbonyl-1-butyl]-L-alanine and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride were mixed in THF and stirred for about 10 min at t° = 20-25° under nitrogen. To the resulting solution contained complex I was added (2S, 3aS, 7aS)-benzyl-perhydroindole-2-carboxylate at t° = 20-25° under nitrogen, and after separation and purification 1.5 g of perindopril benzyl ester was obtained, which was transformed into perindopril tert-Bu amine salt.

RX(1) OF 3 A + B ===> C...

RCT A 82834-12-6 RX (1) STAGE (1) RGT D 3945-69-5 Morpholinium, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-, chloride (1:1)SOL 109-99-9 THF CON 10 minutes, 20 - 25 deg C STAGE (2) RCT B 83508-14-9 CON 5 - 6 hours, 20 - 25 deg C PRO C 122454-52-8

ANSWER 4 OF 15 CASREACT COPYRIGHT 2009 ACS on STN L2 ACCESSION NUMBER: 146:184735 CASREACT Full-text TITLE: Process for manufacture of (2S, 3aS, 7aS) - 1 - [(2S) - 2 - [[(1S) - 1 -(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1Hindole-2-carboxylic acid (perindopril) and its tert-butyl amine salt INVENTOR(S): Gunjal, Sanjay Tukaram; Jadhav, Dilip Uttam; Kumar,

Ashok; Arpana, Mathur; Panda, Nalinakshya Balaram;

Soudagar, Satish Rajanikant

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S.

Ser. No. 140,226.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. DATE |
|-----------------------|------|----------|-------------------------|
| HG 20070021400 | 7.1 | 20070105 | HG 2006 204240 20060102 |
| US 20070021490 | A1 | 20070125 | US 2006-324349 20060103 |
| IN 2005MU00017 | A | 20060811 | IN 2005-MU17 20050106 |
| US 20060178422 | A1 | 20060810 | US 2005-140226 20050527 |
| PRIORITY APPLN. INFO. | : | | IN 2005-MU17 20050106 |
| | | | US 2005-140226 20050527 |
| | | | TN 2004-MU566 20040518 |

OTHER SOURCE(S): MARPAT 146:184735

AB The invention relates to the preparation of perindopril [(2S, 3aS, 7aS)-1-[(2S)-2-[(S)-1-

(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid], its salts, and its novel intermediates, specifically aralkyl ester salts. Thus, (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid was treated with N-[(S)-1-(ethoxycarbonyl)butyl]-L-alanine in CH2Cl2 in the presence of Et3N, 1-hydroxybenzotriazole, and dicyclohexylcarbodiimide to afford 99% perindopril benzyl ester. Conversion of the latter into the oxalate salt, followed by hydrogenolysis over 5% Pd/C and reaction with tert-butylamine yielded perindopril erbumine.

RX(1) OF 38 A + B ===> C...

$$A: CM \ 2$$

Me

HO3S

HO4

 $A: CM \ 2$

HO4

 $A: CM \ 2$

B

C YIELD 99%

RX(1) RCT A 94062-52-9

STAGE (1)

RGT D 121-44-8 Et3N SOL 75-09-2 CH2C12 CON 20 - 25 deg C

STAGE (2)

RCT B 82834-12-6

RGT E 2592-95-2 1-Benzotriazolol, F 538-75-0 DCC

CON SUBSTAGE(1) 15 minutes, 20 - 25 deg C

SUBSTAGE(2) 20 - 25 deg C

PRO C 122454-52-8

L2 ANSWER 5 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 146:45750 CASREACT Full-text

TITLE: Process for the preparation of perindopril

INVENTOR(S): Sinha, Brajesh Kumar; Vaddi, Pandu Ranga Rao; Budidet,

Shankar Reddy; Dandala, Ramesh; Meenakshisunderam,

Sivakumaran

PATENT ASSIGNEE(S): Aurobindo Pharma Limited, India

SOURCE: PCT Int. Appl., 16pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | | | KII | ND | DATE | | | A) | PPLI | CATI | ON NO | ο. | DATE | | | | |
|------------|-------|-------|-----|-----|------|------|------|-----|------|------|-------|-------|------|-------|------|-----|-----|
| | | | | | | | | | | | | | | | | | |
| WO | 20063 | 13182 | 28 | A. | 1 | 2006 | 1214 | | M(| 20 | 06-II | 31583 | 3 | 20060 | 0601 | | |
| | W: | ΑE, | AG, | ΑL, | AM, | ΑT, | ΑU, | ΑZ, | BA, | BB, | BG, | BR, | BW, | BY, | ΒZ, | CA, | CH, |
| | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, |
| | | GE, | GH, | GM, | HR, | ΗU, | ID, | IL, | IN, | IS, | JP, | KΕ, | KG, | ΚM, | KN, | KΡ, | KR, |
| | | KΖ, | LC, | LK, | LR, | LS, | LT, | LU, | LV, | LY, | MA, | MD, | MG, | MK, | MN, | MW, | MX, |
| | | MΖ, | NA, | NG, | NΙ, | NO, | NΖ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | SC, | SD, | SE, |
| | | SG, | SK, | SL, | SM, | SY, | ТJ, | TM, | TN, | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, |
| | | VN, | YU, | ZA, | ZM, | ZW | | | | | | | | | | | |
| | RW: | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | HU, | IE, |
| | | IS, | ΙΤ, | LT, | LU, | LV, | MC, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR, | BF, | ВJ, |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM

IN 2005CH00703 A 20070727 IN 2005-CH703 20050608 IN 2005CH01355 A 20070928 IN 2005-CH1355 20050926 PRIORITY APPLN. INFO.: IN 2005-CH703 20050608 IN 2005-CH1355 20050926

OTHER SOURCE(S): MARPAT 146:45750

AB An improved process for the preparation of perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(S)-1-

(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] comprises treating (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid benzyl ester p-toluenesulfonic acid salt with N-[(S)-1-(ethoxycarbonyl)butyl]-L-alanine [e.g., in MeCN in the presence of 4-(dimethylamino)pyridine], followed by hydrogenolysis of perindopril benzyl ester over 5% Pd/C.

RX(2) OF 4 A + B ===> I...

(2)

STAGE (1)

RGT D 7693-46-1 ClCO2C6H4NO2-4, J 121-44-8 Et3N

SOL 141-78-6 AcOEt

CON SUBSTAGE(1) 0 - 10 deg C

SUBSTAGE(2) 10 deg C -> 20 deg C SUBSTAGE(3) 1 hour, 20 - 25 deg C

STAGE (2)

RGT K 2592-95-2 1-Benzotriazolol

CON SUBSTAGE(1) 20 - 25 deg C

SUBSTAGE(2) 10 minutes, 20 - 25 deg C

STAGE (3)

RCT B 94062-52-9

RGT J 121-44-8 Et3N

CON SUBSTAGE(2) 20 - 30 deg C

STAGE (4)

RGT E 1122-58-3 4-DMAP

4

CON SUBSTAGE(2) 3 hours, 30 - 35 deg C

PRO I 122454-52-8

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2ANSWER 6 OF 15 CASREACT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 145:230528 CASREACT Full-text

TITLE: Process for making highly pure perindopril erbumine INVENTOR(S): Kumar, Ashok; Soudagar, Satish Rajanikant; Mathur, Arpana; Shah, Chirag Hasmukh; Gunjal, Sanjay Tukaram;

Metil, Dattatray Shamrao; Kelkar, Rahul Suresh;

Thakare, Devendra Digambar; Kumar, Bindu Manoj; Nair,

Raji

PATENT ASSIGNEE (S): USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|------|----------|-----------------|----------|
| | | | | |
| US 20060178422 | A1 | 20060810 | US 2005-140226 | 20050527 |
| IN 2004MU00566 | A | 20060616 | IN 2004-MU566 | 20040518 |
| US 20070021490 | A1 | 20070125 | US 2006-324349 | 20060103 |
| PRIORITY APPLN. INFO. | : | | IN 2004-MU566 | 20040518 |
| | | | IN 2005-MU17 | 20050106 |
| | | | US 2005-140226 | 20050527 |

AΒ A process for the synthesis and isolation of (2S, 3aS, 7aS)-1-[(2S)-2-[[(1S)-1-(2S)-2-[(1S)-1-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)(ethoxycarbonyl)butyl]amino]-1- oxopropyl]octahydro-1H-indole-2-carboxylic acid and its tert-butylamine salt, comprises the amidation of (2S, 3aS, 7aS) octahydroindole-2-carboxylic acid benzyl ester and N-[(S)1-carboxybutyl]-(S)alanine Et ester in nonreactive solvents in turn avoiding the formation of the impurity N-acetyl (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester. The de-protection of benzyl ester group is optimized by catalytic

hydrogenolysis and then isolation of the product from an aqueous layer by extraction using an organic solvent, which eliminates the need for lyophilization. This yields perindopril erbumine free of contaminants derivable from dicyclohexylcarbodiimide (e.g., dicyclohexylurea) and impurities originated by the use of Et acetate.

$$RX(1)$$
 OF 3 A + B ===> C...

$$A: CM \ 2$$

HO3S

 $A: CM \ 2$
 $A: CM \ 2$
 $A: CM \ 2$
 $A: CM \ 2$
 $A: CM \ 2$

$$\stackrel{(1)}{\longrightarrow}$$

C YIELD 99%

L2

RX(1) RCT A 94062-52-9, B 82834-12-6 RGT D 538-75-0 DCC, E 121-44-8 Et3N PRO C 122454-52-8 SOL 75-09-2 CH2C12 CON SUBSTAGE(1) 0.25 hours, room temperature SUBSTAGE(2) 20 - 25 deg C ACCESSION NUMBER: 145:124844 CASREACT Full-text TITLE:

Process for the synthesis of

(2S, 3aS, 7aS) -1-(S) -alanyloctahydro-1H-indole-2-

carboxylic acid derivatives and use in the synthesis

of perindopril

Kumar, Ashok; Soudagar, Satish Rajanikant; Mathur, INVENTOR(S):

Arpana; Gunjal, Sanjay Tukaram; Panda, Nalinakshya

Balaram; Jadhav, Dilip Uttam

IPCA Laboratories Limited, India PATENT ASSIGNEE (S):

Eur. Pat. Appl., 16 pp. SOURCE:

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| P | PATENT NO. | | | | KII | ND | DATE | | | A) | PPLI | CATI | N NC | Ο. | DATE | | | |
|--------|------------|-------|------|------|----------|-----|------|------|-----|--------------|------|---------------|------|-----|------|------|----------|-----|
| _ | | | | | | | | | | | | | | | | | | |
| E | Ρ | 16790 | 072 | | A. | 1 | 2006 | 0712 | | E | P 20 | 05-13 | 1309 | 9 | 2005 | 1230 | | |
| E | Р | 16790 | 072 | | В: | 1 | 2008 | 0924 | | | | | | | | | | |
| | | R: | AT, | BE, | CH, | DE, | DK, | ES, | FR, | GB, | GR, | IT, | LI, | LU, | NL, | SE, | MC, | PT, |
| | | | ΙE, | SI, | LT, | LV, | FΙ, | RO, | MK, | CY, | AL, | TR, | BG, | CZ, | EE, | HU, | PL_{r} | SK, |
| | | | ΒA, | HR, | IS, | YU | | | | | | | | | | | | |
| I | Ν | 20051 | MU00 | 017 | Α | | 2006 | 0811 | | II | N 20 | 05-MI | U17 | | 2005 | 0106 | | |
| A | Т | 40903 | 36 | | ${ m T}$ | | 2008 | 1015 | | A' | Г 20 | 05-13 | 1309 | 9 | 2005 | 1230 | | |
| E | Р | 19878 | 828 | | A. | 1 | 2008 | 1105 | | E | P 20 | 08-10 | 0499 | C | 2005 | 1230 | | |
| | | R: | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, | FI, | FR, | GB, | GR, | ΗU, | ΙE, |
| | | | IS, | ΙT, | LI, | LT, | LU, | LV, | MC, | NL, | PL, | PT, | RO, | SE, | SI, | SK, | TR | |
| PRIORI | ΤY | APP | LN. | INFO | . : | | | | | II | N 20 | 05 - M | U17 | | 2005 | 0106 | | |
| | | | | | | | | | | \mathbf{E} | P 20 | 05-13 | 1309 | 9 | 2005 | 1230 | | |

The invention relates perindopril [(2S, 3aS, 7aS)-1-[(2S)-2-[(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)-1-(S)AΒ (ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] aralkyl ester salts used in the synthesis of perindopril. Thus, (2S,3aS,7aS)octahydro-1H-indole-2-carboxylic acid was treated with N-[(S)-1-(ethoxycarbonyl)butyl]-L-alanine in CH2Cl2 in the presence of Et3N, 1hydroxybenzotriazole, and dicyclohexylcarbodiimide to afford 99% perindopril benzyl ester. Conversion of the latter into the oxalate salt, followed by hydrogenolysis over 5% Pd/C and reaction with tert-butylamine yielded perindopril erbumine.

RX(1) OF 34 Α В

$$A: CM 2$$

Me

HO3S

HO Ph

HO

NH

NH

OEt

C YIELD 99%

RCT A 94062-52-9, B 82834-12-6 RX (1)

RGT D 121-44-8 Et3N, E 2592-95-2 1-Benzotriazolol

PRO C 122454-52-8

75-09-2 CH2C12 SOL

CON SUBSTAGE(1) 20 - 25 deg C

SUBSTAGE(2) 0.25 hours, 20 - 25 deg C

SUBSTAGE(3) 20 - 25 deg C

REFERENCE COUNT: THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS 6

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 8 OF 15 CASREACT COPYRIGHT 2009 ACS on STN

142:430514 CASREACT Full-text ACCESSION NUMBER:

TITLE: 2'-Benzothiazolylthioesters of N-substituted alpha

amino acids: versatile intermediates for synthesis of

ACE inhibitors

AUTHOR(S): Singh, Girij Pal; Godbole, Himanshu M.; Nehate, Sagar

P.; Mahajan, Pravin R.

CORPORATE SOURCE: Lupin Research Park, Lupin Ltd., Pune, India SOURCE:

Synthetic Communications (2005), 35(2), 243-248

CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

ACE (angiotensin-converting enzyme) inhibitors have been synthesized in high ABdiastereomeric selectivity by condensation of novel activated amino esters with cyclic amino acid esters using simple reaction conditions. The activated amino esters may be obtained from the corresponding carboxylic acids or their acid chlorides by activation with 2-mercapto-benzothiazole.

RX(5) OF 19 ...C + O ===> P...

 $\stackrel{(5)}{\longrightarrow}$

AIETD 80%

RX(5) RCT C 827622-31-1, O 83508-14-9

STAGE (1)

RGT M 121-44-8 Et3N

SOL 75-09-2 CH2C12

CON 4 hours, -15 - -10 deg C

STAGE (2)

RGT Q 1310-73-2 NaOH

SOL 7732-18-5 Water

CON 2 hours, pH 8.3 - 8.6

PRO P 122454-52-8

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 142:156329 CASREACT <u>Full-text</u>

TITLE: Preparation of α -amino acid benzothiazolylthio

esters as intermediates for manufacture of ACE

inhibitors

INVENTOR(S): Singh, Girij Pal; Godbole, Himanshu Madhav; Mahajan,

Pravin Raghunath; Nehate, Sagar Purushottam

PATENT ASSIGNEE(S): Lupin Limited, India SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PA | PATENT NO. | | | | ND | DATE | | | A | PPLI | CATI | ON NO | ο. | DATE | | | |
|---------------------------|---------------------|------|------|----------|-------|------|------|------|----------------|------|------|-------------------|-----|------|---------------------------|-----|-----|
| WO. | 2005 | 0100 | 28 | A | 1 | 2005 | 0203 | | M _c | 0 20 | 03-I | N257 | | 2003 | 0731 | | |
| | W: | ΑE, | AG, | AL, | AM, | ΑT, | ΑU, | AZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | $\mathrm{GD}_{m{\prime}}$ | GE, | GH, |
| | | GM, | HR, | HU, | ID, | ΙL, | IN, | IS, | JP, | ΚE, | KG, | KΡ, | KR, | KΖ, | LC, | LK, | LR, |
| | | LS, | LT, | LU, | LV, | MΑ, | MD, | MG, | MK, | MN, | MW, | MX, | MΖ, | NΙ, | NO, | NZ, | OM, |
| | | PG, | PH, | PL_{r} | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SY, | ΤJ, | TM, | TN, |
| | | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | ZW | | | |
| | RW: | GH, | GM, | ΚE, | LS, | MW, | MΖ, | SD, | SL, | SZ, | ΤZ, | UG, | ZM, | ZW, | AM, | ΑZ, | BY, |
| | | KG, | KΖ, | MD, | RU, | ТJ, | TM, | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, | EE, | ES, |
| | | FI, | FR, | GB, | GR, | HU, | IE, | IT, | LU, | MC, | NL, | PT, | RO, | SE, | SI, | SK, | TR, |
| | | BF, | ΒJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML_{r} | MR, | NE, | SN, | TD, | TG |
| AU 2003272077 A1 20050214 | | | | | | | 0214 | | A | U 20 | 03-2 | 7207 | 7 | 2003 | 0731 | | |
| PRIORIT | Y APP | LN. | INFO | . : | | | | | M | 0 20 | 03-I | N257 | | 2003 | 0731 | | |
| OTHER S | THER SOURCE(S): MAR | | | | | | | 1563 | 29 | | | | | | | | |

The invention relates to esters (S,S)-RCH2CH2CH(CO2R1)NHCHR2CO-X (I; R is alkyl or Ph; R1 H or alkyl; R2 is alkyl or aminoalkyl; X is 2-benzothiazolylthio) which are intermediates in the manufacture of ACE inhibitors I (X is an amino acid or derivative). The intermediate benzothiazolylthio esters were prepared by reaction of the appropriate acid or acid chloride with 2,2'-dithiobis(benzthiazole) or 2-mercaptobenzothiazole. Thus, treatment of N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-N6-(trifluoroacetyl)-L-lysine (preparation given) with 2,2'-dithiobis(benzothiazole), followed by coupling with L-proline Et ester and deprotection, afforded lisinopril dihydrate.

RX(6) OF 48 ...R + C ===> S...

S YIELD 80%

RX(6) RCT R 83508-14-9

STAGE (1)

RGT E 121-44-8 Et3N SOL 75-09-2 CH2C12

CON SUBSTAGE(1) 25 - 30 deg C

SUBSTAGE(2) 30 deg C -> 15 deg C

STAGE (2)

RCT C 827622-31-1

CON SUBSTAGE(1) 1 hour

SUBSTAGE(2) 25 - 30 deg C SUBSTAGE(3) 8 - 10 hours

STAGE (3)

RGT T 7732-18-5 Water

PRO S 122454-52-8

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 141:411226 CASREACT Full-text

TITLE: Process for preparation of perindopril and its salts

INVENTOR(S): Kankan, Rajendra Narayanrao; Rao, Dharmaraj

Ramachandra

PATENT ASSIGNEE(S): Cipla Limited, India; Wain, Christopher Paul

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| | PAT | ENT 1 | NO. | | KII | ND | DATE | | | A. | PPLI | CATI | N NC | Ο. | DATE | | | |
|------|-----------------------|-------|------|-------------------|--------|-----|-------|----------|------|----------------|------|----------------|------|-----|----------|----------------------|-----|-----|
| | WO | 2004 | 0991 | 38 | A: | 2 | 2004: | 1118 | | M _c | 0 20 | 04-G | B202 | 9 | 2004 | 0512 | | |
| | WO | 2004 | 0991 | 38 | A. | 3 . | 2004 | 1223 | | | | | | | | | | |
| | | W: | ΑE, | AG, | ΑL, | AM, | ΑT, | ΑU, | ΑZ, | BA, | BB, | BG, | BR, | BW, | BY, | BZ, | CA, | CH, |
| | | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | GD, |
| | | | GE, | GH, | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | ΚE, | KG, | KΡ, | KR, | KΖ, | LC, |
| | | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MΖ, | NA, | NΙ, |
| | | | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SY, |
| | | | ΤJ, | TM, | TN, | TR, | TT, | TZ, | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | ZW |
| | | RW: | BW, | GH, | GM, | ΚE, | LS, | MW, | MΖ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, |
| | | | AZ, | BY, | KG, | KΖ, | MD, | RU, | ΤJ, | TM, | AT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, |
| | | | EE, | ES, | FI, | FR, | GB, | GR, | HU, | IE, | IT, | LU, | MC, | NL, | PL_{r} | PT, | RO, | SE, |
| | | | SI, | SK, | TR, | BF, | ΒJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | $\mathrm{ML}_{m{r}}$ | MR, | NE, |
| | | | SN, | TD_{r} | TG | | | | | | | | | | | | | |
| | IN | 20031 | MU00 | 468 | Α | | 2005 | 0211 | | I | N 20 | 03 -M 1 | U468 | | 2003 | 0512 | | |
| PRIO | RIORITY APPLN. INFO.: | | | | | | | | | I | N 20 | 03-M | U468 | | 2003 | 0512 | | |
| OTHE | HER SOURCE(S): | | | | | | PAT : | 141: | 4112 | 26 | | | | | | | | |

AB A process for preparing perindopril or a pharmaceutically-acceptable salt comprises esterifying (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid (I) with benzyl alc. (or the 4-chloro or 4-alkoxy derivative) in the presence of benzenesulfonic acid as catalyst, treating the intermediate ester benzenesulfonate with N-[(S)-1-carbethoxybutyl]-L-alanine (II), and ester cleavage. Thus, I benzyl ester benzenesulfonate (40 g) was prepared, its suspension in CH2C12 made alkaline with aqueous ammonia, and the organic layer separated Treatment with II at 10-15 °C in the presence of hydroxybenzotriazole and N,N'-dicyclohexylcarbodiimide and workup afforded 43 g perindopril benzyl ester.

RX(3) OF 10 G + H ===> I..

$$G: CM 1$$

$$H$$

$$H$$

$$N$$

$$O$$

$$C1$$

$$G: CM 2$$

HO NH OEt

$$n-Pr$$
 (3)

RX(3) RCT G 793716-55-9

Ι

STAGE (1)

RGT J 7664-41-7 NH3

SOL 7732-18-5 Water, 75-09-2 CH2C12

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) room temperature

SUBSTAGE(3) 0.5 hours, room temperature

STAGE (2)

RCT H 82834-12-6

RGT K 2592-95-2 1-Benzotriazolol, L 538-75-0 DCC

SOL 75-09-2 CH2C12

CON SUBSTAGE (1) 10 - 15 deg C

SUBSTAGE(2) 10 - 15 deg C

PRO I 793716-56-0

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 141:395815 CASREACT <u>Full-text</u>

TITLE: A process for the preparation of perindopril using

tetramethyluronium salts as coupling reagents

INVENTOR(S): Rucman, Rudolf

PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2004099236 A1 20041118 WO 2004-SI20 20040507

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

```
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     SI 21506
                       Α
                             20041231
                                            SI 2003-118
                                                              20030508
     EP 1628995
                             20060301
                                            EP 2004-731809
                                                              20040507
                       A1
     EP 1628995
                             20070627
                       В1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     AT 365745
                             20070715
                                            AT 2004-731809
                                                              20040507
                       Т
     ES 2287725
                       Т3
                             20071216
                                            ES 2004-731809
                                                              20040507
     US 20070173637
                       A1
                             20070726
                                            US 2006-555848
                                                              20061026
PRIORITY APPLN. INFO.:
                                            SI 2003-118
                                                              20030508
                                            WO 2004-SI20
                                                              20040507
```

OTHER SOURCE(S): MARPAT 141:395815

AB A process for the preparation of the ACE inhibitor perindopril involves activation of N-[1(S)-(ethoxycarbonyl)butyl]-(S)-alanine (1) with a tetramethyluronium salt in the presence of a tertiary organic base, coupling with (2S,3aS,7aS)-octahydroindole-2-carboxylic acid (2) or an ester, and deprotection. Thus, a mixture of 1, 2 benzyl ester, TBTU and disopropylethylamine in DMF/CH2C12 was stirred for 4 h to afford benzyl-perindopril, which was converted to perindopril by phase transfer or classical hydrogenation.

RX(2) OF 4 F + G ===> A...

A YIELD 98%

RX(2) RCT F 82834-12-6

STAGE (1)

RGT H 125700-67-6 Benzotriazolium der, I 7087-68-5 EtN(Pr-i)2

SOL 75-09-2 CH2Cl2, 68-12-2 DMF

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) 10 minutes, room temperature

STAGE (2)

RCT G 83508-14-9

SOL 75-09-2 CH2C12

CON SUBSTAGE(1) room temperature

SUBSTAGE(2) 4 hours, room temperature

PRO A 122454-52-8

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 141:243833 CASREACT Full-text

TITLE: Process for preparation of perindopril and its salts INVENTOR(S): Datta, Debashish; Singh, Girij Pal; Godbole, Himanshu

Madhav; Siyan, Rajinder Singh

PATENT ASSIGNEE(S): Lupin Limited, India SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PAT | PATENT NO. | | | | ND : | DATE | | | A. | PPLI | CATI | N NC | ο. | DATE | | | |
|-----|------------|------|-----|-----|------|------|------|-----|-------|------|-------|------|-----|------|------|-----|-----|
| | | | | | | | | | _ | | | | | | | | |
| WO. | 2004 | 0758 | 89 | A. | 1 : | 2004 | 0910 | | M_0 | 20 | 03-II | N42 | | 2003 | 0228 | | |
| | W: | ΑE, | AG, | AL, | AM, | ΑT, | ΑU, | ΑZ, | BA, | BB, | BG, | BR, | BY, | ΒZ, | CA, | CH, | CN, |
| | | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | ES, | FI, | GB, | GD, | GE, | GH, |
| | | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | ΚE, | KG, | KΡ, | KR, | KΖ, | LC, | LK, | LR, |
| | | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MΖ, | NO, | NZ, | OM, | PH, |
| | | PL, | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | ΤJ, | TM, | TN, | TR, | TT, | TZ, |
| | | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | ZW | | | | | | |
| | RW: | GH, | GM, | KΕ, | LS, | MW, | MΖ, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | ΑM, | ΑZ, | BY, |

```
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2517205
                             20040910
                                            CA 2003-2517205
                                                             20030228
                       Α1
     AU 2003224420
                             20040917
                                            AU 2003-224420
                                                              20030228
                       Α1
     EP 1603558
                       A1
                             20051214
                                            EP 2003-720846
                                                              20030228
     EP 1603558
                       В1
                             20080521
         R:
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006519168
                             20060824
                                            JP 2004-568714
                                                              20030228
     AT 395913
                        Т
                                            AT 2003-720846
                             20080615
                                                              20030228
     ES 2307923
                        Т3
                                            ES 2003-720846
                             20081201
                                                              20030228
     US 20060276659
                       A1
                             20061207
                                            US 2006-547243
                                                              20060621
PRIORITY APPLN. INFO.:
                                            WO 2003-IN42
                                                              20030228
```

OTHER SOURCE(S): MARPAT 141:243833

A process for the preparation of perindopril and its salts involves reaction of N-[1(S)-(ethoxycarbonyl)butyl]-L-alanyl chloride (I) or bromide with (2S)indolinecarboxylic acid benzyl ester or its hexahydro derivative, followed by catalytic hydrogenation. Thus, perindopril benzyl ester was prepared by adding a slurry of 1.88 g I (preparation given) to a solution of 1.6 g (2S, 3aS, 7aS) -octahydroindole-2-carboxylic acid benzyl ester and triethylamine in CH2Cl2 at -10 to 15° over 25-30 min. Hydrogenation of the benzyl ester over 10% Pd-C afforded 1.3 g perindopril.

RX(6) OF 28 \dots T + B ===> F \dots

RX(6) RCT T 83508-14-9, B 748154-69-0

STAGE (1)

RGT U 121-44-8 Et3N SOL 75-09-2 CH2C12

CON SUBSTAGE(1) 25 - 30 minutes SUBSTAGE(2) 25 - 30 deg C

STAGE (2)

RGT N 7732-18-5 Water

PRO F 122454-52-8

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 140:375491 CASREACT Full-text

TITLE: Method for the synthes is of perindopril and its

pharmaceutically-acceptable salts

INVENTOR(S): Dubuffet, Thierry; Lecouve, Jean-Pierre

PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.

SOURCE: Eur. Pat. Appl., 6 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PA! | PATENT NO. KIND DATE | | | | | | | A | PPLI | CATI | N NC | Ο. | DATE | | | | |
|-----|----------------------|------|-----|------------------|---------|------|----------------------|------|------|------|------|------|------|------|------|-----|-----------------|
| EP | 1420 | | | A: | | 2004 | 0519 | | E | P 20 | 03-2 | 9308 | 4 | 2003 | 1210 | | |
| EP | 1420 | 029 | | A. | 3 | 2004 | 0526 | | | | | | | | | | |
| EP | 1420 | 029 | | В: | 1 | 2008 | 0220 | | | | | | | | | | |
| | R: | ΑT, | BE, | CH, | DE, | DK, | ES, | FR, | GB, | GR, | ΙT, | LI, | LU, | NL, | SE, | MC, | PT, |
| | | ΙE, | SI, | LT, | LV, | FI, | RO, | MK, | CY, | AL, | TR, | BG, | CZ, | EE, | ΗU, | SK | |
| AT | 3867 | 45 | | ${ m T}$ | | 2008 | 0315 | | Α | Т 20 | 03-2 | 9308 | 4 | 2003 | 1210 | | |
| ES | 2300 | 555 | | \mathbf{T}^{2} | 3 | 2008 | 0616 | | E | S 20 | 03-2 | 9308 | 4 | 2003 | 1210 | | |
| AU | 2004 | 3121 | 85 | A. | 1 | 2005 | 0721 | | A | U 20 | 04-3 | 1218 | 5 | 2004 | 1209 | | |
| CA | 2548 | 405 | | A. | 1 | 2005 | 0721 | | C. | A 20 | 04-2 | 5484 | 05 | 2004 | 1209 | | |
| WO | 2005 | 0661 | 98 | A. | 1 | 2005 | 0721 | | W | 0 20 | 04-F | R316 | 6 | 2004 | 1209 | | |
| | W: | ΑE, | AG, | AL, | AM, | ΑT, | ΑU, | AZ, | BA, | BB, | BG, | BR, | BW, | BY, | ΒZ, | CA, | CH, |
| | | CN, | CO, | CR, | CU, | CZ, | DE, | DK, | DM, | DZ, | EC, | EE, | EG, | ES, | FI, | GB, | ${ m GD}_{m r}$ |
| | | GΕ, | GH, | GM, | HR, | HU, | ID, | IL, | IN, | IS, | JP, | ΚE, | KG, | KP, | KR, | KΖ, | LC, |
| | | LK, | LR, | LS, | LT, | LU, | LV, | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MΖ, | NA, | NI, |
| | | NO, | NZ, | OM, | PG, | PH, | PL, | PT, | RO, | RU, | SC, | SD, | SE, | SG, | SK, | SL, | SY, |
| | | ТJ, | TM, | TN, | TR, | TT, | $\mathrm{TZ}_{m{r}}$ | UA, | UG, | US, | UZ, | VC, | VN, | YU, | ZA, | ZM, | ZW |
| | RW: | BW, | GH, | GM, | KE, | LS, | MW, | MΖ, | NA, | SD, | SL, | SZ, | TZ, | UG, | ZM, | ZW, | AM, |
| | | ΑZ, | BY, | KG, | ΚZ, | MD, | RU, | ΤJ, | TM, | ΑT, | BE, | BG, | CH, | CY, | CZ, | DE, | DK, |
| | | EE, | ES, | FI, | FR, | GB, | GR, | HU, | ΙE, | IS, | IT, | LT, | LU, | MC, | NL, | PL, | PT, |
| | | RO, | SE, | SI, | SK, | TR, | BF, | ΒJ, | CF, | CG, | CI, | CM, | GA, | GN, | GQ, | GW, | ML, |
| | | MR, | ΝE, | SN, | TD, | TG | | | | | | | | | | | |
| CN | 1890 | 258 | | Α | | 2007 | 0103 | | C | N 20 | 04-8 | 0036 | 354 | 2004 | 1209 | | |
| BR | BR 2004017423 A | | | 2007 | 0306 | | В | R 20 | 04-1 | 7423 | | 2004 | 1209 | | | | |
| JΡ | 2008 | 5058 | 45 | T 2 | | 2008 | 0228 | | J | P 20 | 06-5 | 4358 | 3 | 2004 | 1209 | | |
| IN | 2006 | DN03 | 069 | Α | A 20070 | | 0824 | | I. | N 20 | 06-D | N306 | 9 | 2006 | 0529 | | |
| MX | 2006006562 A | | | | 2006 | 0731 | | M | X 20 | 06-6 | 562 | | 2006 | 0609 | | | |
| US | JS 20070093663 A | | | 1 | 2007 | 0426 | | U | S 20 | 06-5 | 8228 | 3 | 2006 | 0609 | | | |
| US | 7279 | | В | 2 | 2007 | 1009 | | | | | | | | | | | |

| NO 2006003012 | Α | 20060628 | NO | 2006-3012 | 20060628 |
|------------------------|----|----------|----|-------------|----------|
| KR 825537 | В1 | 20080425 | KR | 2006-713586 | 20060706 |
| PRIORITY APPLN. INFO.: | | | EP | 2003-293084 | 20031210 |
| | | | WO | 2004-FR3166 | 20041209 |

AB A method for the synthesis of perindopril involves coupling of (2S)-indoline-2-carboxylic acid benzyl ester or (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester with N-[(S)-1-carbethoxybutyl]-L-alanine in the presence of a coupling agent [e.g., O-(benzotriazol-1-yl)-1,1,3,3-bis(tetramethylene)uronium hexafluorophosphate], followed by hydrogenation over Pd. Perindopril was converted into its tert-butylamine salt.

RX(1) OF 4 A + B ===> C...

(1)

RX(1) RCT A 94062-52-9

STAGE (1) RGT D 121-44-8 Et3N SOL 141-78-6 AcOEt

CON 10 minutes, room temperature

STAGE (2)

RCT B 82834-12-6

RGT E 105379-24-6 1H-Benzotriazolium,

1-(di-1-pyrrolidinylmethylene)-, 3-oxide,

hexafluorophosphate(1-) (1:1)

CON SUBSTAGE(1) room temperature -> 30 deg C

SUBSTAGE(2) 3 hours, 30 deg C

PRO C 122454-52-8

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 14 OF 15 CASREACT COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 135:167034 CASREACT Full-text

TITLE: Method for synthesis of perindopril and its

pharmaceutically acceptable salts

INVENTOR(S): Langlois, Pascal; Turbe, Hugues

PATENT ASSIGNEE(S): Adir et Compagnie, Fr. SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND DATE | APPLICATION NO. DATE |
|---------------|---------------------------|-----------------------------------------|
| WO 2001058868 | A1 20010816 | WO 2001-FR1026 20010405 |
| W: AE, AG, | AL, AM, AT, AU, | AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, |
| CO, CR, | CU, CZ, DE, DK, | DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, |
| HR, HU, | ID, IL, IN, IS, | JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, |
| LT, LU, | LV, MA, MD, MG, | MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, |
| RU, SD, | SE, SG, SI, SK, | SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, |
| VN, YU, | ZA, ZW | |
| RW: GH, GM, | KE, LS, MW, MZ, | SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, |
| DE, DK, | ES, FI, FR, GB, | GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, |
| BJ, CF, | CG, CI, CM, GA, | GN, GW, ML, MR, NE, SN, TD, TG |
| | A1 20011012 | FR 2000-4379 20000406 |
| | B1 20020719 | |
| HU 2001001336 | A2 20020228 | HU 2001-1336 20010330 |
| | A3 20030328 | |
| | A1 20010816 | CA 2001-2405486 20010405 |
| | C 20080729 | |
| | A 20010820 | |
| | A1 20030102 | EP 2001-921486 20010405 |
| | B1 20070808 | |
| | | FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, |
| | LT, LV, FI, RO, | |
| | | BR 2001-9836 20010405 |
| | | JP 2001-558419 20010405 |
| JP 3939553 | B2 20070704 A 20040326 | |
| NZ 521454 | A 20040326 | |
| | A 20040415 | EE 2002-575 20010405 |
| | B1 20080616 | 0004 040470 000404 |
| AU 2001248470 | B2 20050120 | AU 2001-248470 20010405 |
| | | AP 2002-2630 20010405 |
| CN 1296355 | C 20070124 | CN 2001-807372 20010405 |

| AT | 369338 | T | 20070815 | ΑT | 2001-921486 | 20010405 |
|----------|---------------|----|----------|----|-------------|----------|
| ES : | 2291307 | Т3 | 20080301 | ES | 2001-921486 | 20010405 |
| IN : | 2002MU00598 | A | 20040417 | IN | 2002-MU598 | 20020703 |
| ZA : | 2002007419 | A | 20030916 | ZA | 2002-7419 | 20020916 |
| IN : | 2002MN01284 | A | 20040703 | IN | 2002-MN1284 | 20020918 |
| US : | 20030069431 | A1 | 20030410 | US | 2002-239129 | 20020919 |
| US | 6835843 | В2 | 20041228 | | | |
| MX : | 2002009706 | A | 20040906 | MX | 2002-9706 | 20021002 |
| NO : | 2002004808 | A | 20021004 | NO | 2002-4808 | 20021004 |
| NO | 324174 | В1 | 20070903 | | | |
| BG | 107249 | A | 20030731 | BG | 2002-107249 | 20021104 |
| HK | 1053309 | A1 | 20070511 | HK | 2003-105542 | 20030801 |
| PRIORITY | APPLN. INFO.: | | | FR | 2000-4379 | 20000406 |
| | | | | WO | 2001-FR1026 | 20010405 |
| | | | | | | |

AB Perindopril [(2S,3aS,7aS)-1-[(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl]octahydro-1H-indole-2-carboxylic acid] was prepared by coupling (2S,3aS,7aS)octahydroindole-2-carboxylic acid tosylate with N-[(S)-1-carbethoxybutyl]-(S)-alanine, followed by catalytic hydrogenation to remove the benzyl group. In an example, the coupling reaction was carried out in Et acetate in the presence of Et3N, 1-hydroxybenzotriazole and dicyclohexylcarbodiimide at 30° for 3h to give 92% perindopril benzyl ester.

RX(1) OF 3 A + B ===> C...

$$A: CM 2$$

Me

HO3S

 $A: CM 2$
 $A: CM 2$
 $A: CM 2$
 $A: CM 2$
 $A: CM 2$

C YIELD 92% RX(1) RCT A 94062-52-9, B 82834-12-6

RGT D 121-44-8 Et3N, E 2592-95-2 1-Benzotriazolol, F 538-75-0 DCC

PRO C 122454-52-8

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 15 OF 15 CASREACT COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 109:231529 CASREACT Full-text

TITLE: Synthesis of S9490-3 [U-14C-cyclohexyl]

1-[(2S)2-[(1S)1-(ethoxycarbonylbutyl)amino]-1-oxopropyl]-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid tert-butylamine salt and S9780 [U-14C-cyclohexyl]1-[(2S)2-[(1S)1-(carboxybutyl)amino]-1-oxopropyl]-2S,3aS,7aS)-perhydroindole-2-carboxylic acid and of

[3,4-3H-butylamino]S9490-3 and [(3,4-3H-)butylamino]S9780

AUTHOR(S): Pichat, L.; Tostain, J.; Gomis, J. M.; Coppo, M.;

Moustier, A. M.; Vincent, M.; Remond, G.; Portevin,

B.; Laubie, M.

CORPORATE SOURCE: CEN Saclay, Gif sur Yvette, 91191, Fr.

SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals

(1988), 25(5), 553-68

CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal LANGUAGE: French

GΙ

AB The title 14C-labeled compds. I (* signifies the uniform labeling of the cyclohexane ring with 14C) and II were prepared from aniline-U-14C in several steps. The title 3H-labeled compds. were also prepared The latter synthesis involved the tritiation of an allylglycine residue. The title compds. are potent inhibitors of angiotensin-converting enzyme.

RX(10) OF 69 ...Y + AB ===> A...

RX(10) RCT Y 117770-56-6, AB 82834-12-6 RGT AC 538-75-0 DCC, AD 2592-95-2 1-Benzotriazolol PRO A 117770-57-7 SOL 68-12-2 DMF

=> log off ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF LOGOFF? (Y)/N/HOLD:y STN INTERNATIONAL LOGOFF AT 12:58:34 ON 06 MAR 2009